Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Clinical Gastroenterology and Hepatology(2022)10.1016/j.cgh.2022.07.032Source: DataRank Database

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis is a research paper published in Clinical Gastroenterology and Hepatology (2022). On theSindex it has a DataRank of 0. It has been cited 106 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

106 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 6.36)OA: closedTopics (23)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Antonio Facciorusso ORCID,Tine Jess ORCID,Christopher Ma ORCID,Cesare Hassan ORCID,Alessandro Repici ORCID

Live enrichment

PubMed:35944832 OpenAlex:https://openalex.org/W4293314234

Danmarks Grundforskningsfond

Grant: DNRF148

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: K23DK117058

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: R03DK129631

Fresenius Kabi

Roche

Sandoz

Biogen

Takeda Pharmaceutical Company

Ferring Pharmaceuticals

Fujifilm Corporation

Meso Scale Diagnostics

National Institutes of Health

Janssen Pharmaceuticals

Medtronic

Gilead Sciences

Boston Scientific Corporation

Merck

Pfizer

FWCI

6.36

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S1542356522007327?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542356522007327?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cgh.2022.07.032

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35944832

repositoryhttps://vbn.aau.dk/da/publications/896e72cc-6968-4efd-b07a-97b9f40174e6

Fields of Study

Inflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical Methods

MeSH Terms

UstekinumabBiological FactorsBiological ProductsColitis, UlcerativeCrohn DiseaseHumansTumor Necrosis Factor-alphaInflammatory Bowel Diseases

Keywords

MedicineInflammatory Bowel DiseasesMeta-analysisInflammatory bowel diseaseIntensive care medicineMEDLINEInternal medicineDiseaseComparativePropensity ScoreBiologicsRisk-benefit

Sustainable Development Goals

SDG 0: Good health and well-being

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

FAIR Checklist

Authors (9)

Funding (18 grants)

Impact

Open Access

Topics